drugset / Trial / NCT03266653
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
Phase 2
Recruiting
20 enrolled
New York Medical College
Children's Hospital of Philadelphia · collabIndiana University · collabMedical College of Wisconsin · collabNationwide Children's Hospital · collabUniversity of California, Los Angeles · collabUniversity of California, San Francisco · collabWashington University School of Medicine · collab
NaSingle-groupOpen-labelTreatment
Summary
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Timeline
- Start
- 2020-07-07
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytotoxic T Lymphocytes | Cell therapy | — | — |